Evaluation of the overall survival curves using the Kaplan-Meier method indicated that patients carrying BRCA2 mutations presented a lower breast cancer-specific survival in comparison with those resulted negative for BRCA2 mutations, within the first two years from diagnosis (Figure 1). This evidence concerns the gene BRCA2 and breast carcinoma.